(IBS). - Dietitians in Integrative and Functional Medicine
Transcription
(IBS). - Dietitians in Integrative and Functional Medicine
DIFM-The Integrative RDNs Dietitians in Integrative and Functional Medicine June 25, 2014 Gerard E. Mullin MD Associate Professor of Medicine Johns Hopkins University School of Medicine Division of Gastroenterology & Hepatology Objectives • To examine the pathophysiology of IBS as the foundation for integrative solutions • To review the herbal therapies, dietary supplements and special diets that have proven efficacy in the irritable bowel syndrome • To know the mind-body modalities that improve outcomes for the irritable bowel syndrome. Rome III Criteria for IBS • A chronic disorder characterized by abdominal pain or discomfort associated with disordered defecation • Symptoms should have developed at least 6 months before the patient first presents for formal evaluation • Abdominal pain or discomfort should be present at least 3 days per month for 3 months and should be associated with two or more of the following: – improvement with defecation, – onset associated with a change in stool frequency, and/or – onset associated with a change in stool form. Epidemiology of IBS • Prevalence is 10-15% of US population, F>>>M • Annual direct costs for IBS=$1.35 billion • Estimated impact on the U.S. of $30 billion annually (excluding prescription and OTC meds)(Leong, 2003;Inadomi, 2003;Hulisz, 2004). • IBS adversely impacts quality of life, and, thus, significantly affects work productivity (Dean, 2005; Quigley, 2006). • Consequently, IBS continues to be the second most common cause of work and school absenteeism (Drossman, 1993). • Two decades ago, about 16% of IBS patients had sought out CAM practitioners (Smart, 1986). More recent data indicates that up to 51 percent of patients with IBS report using CAM (Haas, 2000;Kong, 2005). The Pathogenesis of IBS Emerging Options for IBS • Supplements • Gut Microbiome Pathophysiology of IBS Pathophysiology of IBS The Immune System in Irritable Bowel Syndrome. Barbara et al Neuro Gastro Motility October 2011 17;4:349. Evidence to Support a Pivotal Role of Gut Microbiome in IBS • • • • Post-infectious IBS Altered Colonic Microbiome in IBS Probiotics Small Intestine Bacterial Overgrowth Clinical Features Associated with SIBO • • • • • • • Gas-bloat Flatulence Abdominal discomfort Diarrhea Steatorrhea Weight loss Features associated with micronutrient deficiencies Treatment Options for SIBO The goal is to treat the underlying cause(s), eradicate the bacterial overgrowth and nutritional support • Antibiotic therapy • Herbs (berberine, wormwood) • Prokinetic agents • Elimination Diet-FODMAPs Results of IBS Subjects Undergoing Intervention for Positive Lactulose Breath Hydrogen Testing for SIBO (n=104) Glob Adv Health Med. 2014 May;3(3):16-24. Characteristics Rifaximin Number 67 Age (yr), sd, 44.4 +/-14.8 (19range 81) Gender Female N (%) 48 (71) Male n (%) 19 (29) Responses (n) 26 Responses Rate 34 (%) Adverse Events 2, 2.9 (n, %) Herbs 37 41.3 +/- 14.8 (19-76) 29 (78) 8 (22) P value na 0.33 15 46 na 0.24 1, 2.7 .83 .97 Mullin et al Global Advances in Health and Medicine May, 2014 IBS SYMPTOM INDEX Treatment of IBS with TCM 200 180 160 140 120 100 80 60 40 20 0 P=0.10 Placebo Standard Individual P=0.03 Baseline End of Tx N=35 14 N=43 weeks follow up N=38 Level A A Bensoussan, NJ Talley, M Hing et al. Treatment of irritable bowel syndrome with Chinese herbal * medicine. A randomized * controlled study. JAMA 1998 280: 1585-1589 Traditional Chinese Herbal Medicine to Treat IBS Authors N Trial Design Treatment Time Outcome Bensoussan et al 1998 116 R,D,P Standard TCM, Individualized herbs, placebo 16 weeks Significant reduction in symptom scores and QOL Wang et al 2008 24 R, non-D,P 24 gm Shugan Jianpi granules +/Smecta TID or CBT + lacetin 2 weeks Significant reduction in serotonin positive cells in herbal groups Leung et al 2006 119 R,D,P Concoction of Chinese herbs vs. placebo (IBS-D) 8 weeks No significant improvement in SF-36 or global symptoms Bian Z et al 1125 Meta-analysis Tong xie yao fang (TXYF) (IBS-D) 10-40 days More effective than placebo (RR 1.35, 95% CI 1.21-1.50) Sallon S et al 61 R,D,P Padma Lax (IBS-C) 12 weeks More effective than placebo 76% vs. 31% Altern Med Rev. 2011 Jun;16(2):134-51. Iberogast PLANT NAME HERB-EXTRACT RATIO IN 100 ML OF IBEROGAST Bitter candytuft 1:1.5-2.5 15 mL Angelica root 1:2.5-3.5 10 mL Chamomile flowers 1:2.5-4.0 20 mL Caraway fruits 1:2.5-3.5 10 mL Milk thistle 1:2.5-3.5 10 mL Lemon balm 1:2.5-3.5 10 mL Peppermint leaves 1:2.5-3.5 5 mL Celandine 1:2.5-3.5 10 mL Licorice root extract 1:2.5-3.5 10 mL Iberogast Improves IBS Symptoms Madisch, A., Holtmann, G., Plein, K. & Hotz, J. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Alimentary Pharmacology & Therapeutics 19 (3), 271-279. • • • • • Irritable bowel syndrome (IBS) symptom score (± s.d.) for the various treatment groups at baseline and after 2 and 4 weeks of treatment. Intentionto-treat population. *P = 0.0033, §P = 0.0035, **P = 0.0009 and §§P = 0.0005 vs. placebo. STW 5, commercially available herbal preparation (nine plant extracts) STW 5-II, research herbal preparation (six plant extracts) BCT, bitter candytuft mono-extract. Level A Iberogast Improves IBS Pain Madisch, A., Holtmann, G., Plein, K. & Hotz, J. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial.Alimentary Pharmacology & Therapeutics 2004; 19 (3), 271-279. Abdominal Pain score (± s.d.) for the various treatment groups at baseline and after 2 and 4 weeks of treatment. Intention-to-treat population. *P = 0.0085, §P = 0.0006, **P = 0.001 and §§P = 0.0003 vs. placebo. STW 5, commercially available herbal preparation (nine plant extracts) STW 5-II, research herbal preparation (six plant extracts) BCT, bitter candytuft mono-extract. Level A Pharmacological Effects of Iberogast Botanical Inhibition of AntiAcid Inflammation secretion Oxidative stress Hypomotility Hypermotility Peppermint W S S N M Chamomile S W M M S Licorice root W S W N M Angelica root M W M N S Caraway M S W N W Milk thistle M M M N M Melissa leaf M M S N W Celandine N M M M N Bitter candytuft M S W M W Wagner H. Multitarget therapy-the future for more than just functional dyspepsia. Phytomedicine 2006;13 suppl 5:122-129. Peppermint • Animal model studies demonstrate: – relaxation effect on gastrointestinal (GI) tissue – analgesic and anesthetic effects in the central and peripheral nervous system – immunomodulating actions – chemopreventive potential • Blocks calcium channels in gastrointestinal smoothe muscle to produce spasmolytic response Wald A, Rakel D. Nutr Clin Pract. 2008 Jun-Jul;23(3):284-92. Review Cochrane Collaboration 2011 Issue 11. ACG Task Force: Management of IBS-D Agents Grade Antispasmodics RR of IBS symptoms not improving - 0.68 Hyoscine, cimetropium, pinaverium: provide short-term relief of abdominal pain/discomfort inI BS Grade 2C not given Peppermint oil: superior to placebo in IBS in a small number of studies Grade 2B 0.43 Alosetron: more effective than placebo at relieving global IBS symptoms in male and female IBS-D patients. Potentially serious side effects of constipation and colon ischemia (Grade 2A). Grade 2B (M) Grade 2A (F) 0.79 ACG IBS Task Force, Am J Gastro 2009; 104 (S1): S1-S35 Efficacy of Therapies for IBS Therapy BMJ 2008;337: a2313 Trials NNT Peppermint Oil Hycosamine 8 2 22 11 Alosetron 6 7 Tegaserod 8 17 TCAs 8 4 Other Herbal Therapies for IBS Herb/ Reference Sample size Sample characteristics Study design Dose of active Duration Outcome 207 All forms IBS R, non-D, non-P 2 doses, 72 mg (1 tablet) or 144 mg (2 tablets) daily 8 weeks Significant improvement in IBS QOL at end of trial vs. baseline both Tx groups Walker et al 2001 279 All IBS forms R, non-D, non-P 320 mg artichoke leaf extract per cap; 2 TID 6 weeks Significant reduction of IBS symptoms vs. baseline Bundy et al 2004 208 All forms IBS R, non-D, non-P 320 mg (1 capsule) or 640 mg (2 capsules) of 1:5 artichoke leaf extract daily 2011 Jun;16(2):134-51. 8 weeks Significant reduction in QOL, symptom score vs. baseline Tumeric Bundy et al 2004 Artichoke leaf extract Altern Med Rev. Melatonin Sleep Depression Anxiety IBS??? Is Melatonin involved in IBS? JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY 2009, 60, Suppl 3, 67-70 Melatonin in IBS Author-Year Trial Outcome DB, RCT 3 mg melatonin vs. placebo 8 weeks, 4 week washout, 8 week crossover n=17 Improved overall IBS scores, Decreased abdominal pain, decreased abnormal to defecation, decreased distention IBS-C colonic transit study. O3 mg melatonin vs. placebo 8 weeks, 4 week washout, 8 week crossover n=17 Blue dye, radiopaque markers, bristol stools CTT prolonged in IBS-C vs. controls Melatonin increased CTT in vs. placebo No difference in prolongation of CTT with melatonin in Controls vs. IBS-D Saha L et al J Clin Gastro 2007;41;1:29-32. IBS, 3 mg melatonin vs. placebo, 8 weeks, DB RCT N=18 Improved overall IBS score, improved extra-colonic symptoms and QOL Song GH et al Gut 2005;54;10:1402-7. 3 mg melatonin vs. placebo vs. 2 weeks IBS with sleep disturbances N=40 Improved abdominal pain, decreased rectal pain thresholds Lu WZ. Aliment Pharmacol Ther 2005 Nov 15;22;10:92734 Lu WZ et al. Dig Dis Sci 2009; 54;5:1087-95. Emerging Options for IBS • Supplements • Gut Microbiome Distribution of Intestinal Bacterial Flora in Normal Gut and in Small Intestinal Bacterial Overgrowth Lin, H. C. JAMA 2004;292:852-858. Origin of gas/bloating of IBS patients with SIBO IBS Patients on High FODMAP Diet Produce Breath Methane Treatment Options for SIBO The goal is to treat the underlying cause(s), eradicate the bacterial overgrowth, and nutritional support • Antibiotic therapy • Prokinetic agents • Herbs (berberine, oregano oil, wormwood) Mullin et al Global Advances in Health and Medicine May 2014 • Diet • Enzymes/HCl Results of IBS Subjects Undergoing Intervention for Positive Lactulose Breath Hydrogen Testing for SIBO (n=104) Characteristics Rifaximin Number 67 Age (yr), sd, 44.4 +/-14.8 (19range 81) Gender Female N (%) 48 (71) Male n (%) 19 (29) Responses (n) 26 Responses Rate 34 (%) Adverse Events 2, 2.9 (n, %) Herbs 37 41.3 +/- 14.8 (19-76) 29 (78) 8 (22) P value na 0.33 15 46 na 0.24 1, 2.7 .83 .97 Mullin et al Global Advances in Health and Medicine May, 2014 Meta-analysis for Probiotic Use in IBS • Over 20 RCT’s and 5 meta-analysis for probiotics use in IBS • Most systematic reviews indicate that probiotics have a beneficial impact on global IBS symptoms, abdominal pain and flatulence but not bloating. • Strain specific? Current Opinion in Clinical Nutrition & Metabolic Care. 14(6):581-587, November 2011. DOI: 10.1097/MCO.0b013e32834b8082 Meta-analysis for Probiotic Use in IBS • Over 20 RCT’s and 5 meta-analysis for probiotics use in IBS • Most systematic reviews indicate that probiotics have a beneficial impact on global IBS symptoms, abdominal pain and flatulence but not bloating. • Strain specific? Current Opinion in Clinical Nutrition & Metabolic Care. 14(6):581-587, November 2011. . Gut. 2010 Mar;59(3):325-32 Summary of Evidence for Herbal and Micronutrient-based Therapies for IBS INTERVENTION Peppermint oil Melatonin Iberogast TCM Artichoke leaf extract Tumeric BODY OF EVIDENCE 3 meta-analyses of 5, 4 and 3 RCTs 2 RCTs 1 RCT 2 RCTs(+) 1 RCT(-) 1 meta(+) 2 RCTs 1 RCT Summary of Adverse Effects for Herbal and Micronutrient-based Therapies for IBS INTERVENTION ADVERSE EFFECT Peppermint oil Melatonin Iberogast TCM Artichoke leaf extract Tumeric Worsening of GERD Drowsiness Allergy Adulteration (meds, metals) none GI intolerance (Pepperdine) Summary of Evidence for Herbal and Nutraceutical-based Therapies for IBS Therapy Mullin et al JPEN 2014 In Press Description Level of Grades of Evidence Recommendations Bifidobacterium infantis B5624 IA and VSL#3 Other species IA A Prebiotics Food sources include bananas, IB artichokes, onions, asparagus, and chicory. Low doses (3-5 gm) of inulin FOS, GOS. C Fiber Isphagla IA D Peppermint Oil 0.2-0.4 mL enteric-coated capsules 3 times daily IA A Melatonin Iberogast 3 mg at night IB B 20 drops 2-3 times daily IB B Probiotics B Gas Bloating Abdominal Pain Diarrhea Constipation > 60% IBS patients report worsening symptoms after meals, 28% within 15 minutes, 93% within 3 hours Eswaran S, Tack J & Chey W. Food: The Forgotten Factor in the Irritable Bowel Syndrome. Gastroenterol Clin N Am 40 (2011) 141–162 Self-Reported GI Food-Related GI Symptoms in IBS 197 patients with IBS • 84% report food-related symptoms • 70% (138) incompletely absorbed carbohydates • 49% dairy products • 36% Beans and Lentils • 58% biogenic amines: salami (22%), cheese (20%) • High Histamine foods: milk (43%), wine/beer (31%), pork (21%) • 52% Fried and fatty foods Bohn L. Am J Gastroenterol 2013; 108:634–641; Do carbohydrates produce symptoms in IBS? Dairy Grains Fruits and Vegetables Prevalence of Lactose Intolerance in IBS 38% 26% IBS patients (n=251) Controls (n=174) Fructose and Fructans as Dietary Triggers for IBS symptoms * Shepherd, et al, Clin Gastro Hepatol 2008;6:765 * * Very Low CHO Diet for IBS SD VLC SD VLC • 15 females, mean age 46 yrs, BMI 32 • Dietary interventions: – 2 wks standard (55% CHO, – 30% Fat, 15% Protein) – 4 wks VLC (4% CHO, 51% Fat, 45% Protein) • Responder rate: 100% • Improvements in stool frequency p<0.001),consistency (p<0.001), pain (p<0.001), QoL (p=0.02) • Mean weight loss of 3.1 kg Austin et al. Clin Gastro Hepatol 2009;7:706 Emerging Options for IBS • Supplements • Gut Microbiome • Elimination Diets What’s The Difference? Food Allergy • an adverse immune response to the proteins in a food; may occur as the result of a humoral response (immunoglobulin E [IgE] antibody), a cellular response (i.e. T cells), or both Food Intolerance/sensitivity • not a true food allergy: could be enzyme deficiency (e.g. lactase deficiency), chemical reactions, aversion. May also refer to IgG‐mediated reactions or other immune reactions to food. Food Allergy vs. Food Sensitivity Food Allergy • • • • • Type I Hypersensitivity IgE mediated Immediate, rapid onset Systemic, potentially life threatening Shared Symptoms: – Nausea, vomiting, diarrhea, abdominal pain • Different symptoms: – Hives, tingling or itching in the mouth, swelling of the lips, face, tongue and throat, SOB, wheezing, nasal congestion, anaphylaxis Food Sensitivity Type III hypersensitivity IgG mediated Gradual, delayed response Localized, generally limited to the GI tract • Shared Symptoms: • • • • – Nausea, vomiting, diarrhea, abdominal pain • Different symptoms: – Gas, cramps, bloating, heartburn, headaches, irritability, nervousness Food Allergy vs. Food Sensitivity Common Food Allergies: • Dairy • Eggs • Wheat • Soy • Peanuts and tree Nuts • Fish • Chicken • Corn Lack G. NEJM.2008;359:1252 Common Food Sensitivities: • Dairy • Wheat • Peanuts • Tree Nuts Exclusion-Based Diets • Based on Food Hypersensitivity Testing Dairy (IgG4, ALCAT, etc) • Top 8 Food Allergens • Carbs, Lactose, Fructose, FODMAPs, Gluten • Caffeine, Additives, Amines • Elimination Diet Studies of Elimination Diets Evidence that elimination diets based on IgG and IgE food antibodies have shown benefit in IBS Food elimination based on IgG antibodies in irritable bowel syndrome: a randomized controlled trial. P<0.001 Level A Atkinson, W et al. Gut 2004;53:1459-1464 Results of Studies of Immunoglobulin G (IgG) Antibody-Elimination Diets for Irritable Bowel Syndrome (IBS). Mullin GE, Lipski L. et al. Nutr Clin Pract 2010;25:192-198 IgG Elimination Diet in Migraine + IBS • 21 patients (85.7% women) • IgG for 270 foods • RCT/cross-over: usual diet, elimination and provocation • Elimination Diet – < in attack duration, severity, # of migraines – < pain-bloating severity,< occurrence, – > QOL Aydinlar EI. Headache. 2013 Mar;53(3):514-25. A Spectrum of Disease With Overlap? Gluten Sensitivity Motility/Visceral Brain-Gut Interactions Neurological Musculoskeletal pain Altered Permeability? IBS Motility/Visceral Sensation Brain-Gut Interactions Immune activation Altered Gut Microbiome Altered Permeability Celiac Disease Motility/Visceral Sensation Brain-Gut Interactions Neurological Immune activation Altered Gut Microbiome Altered Permeability Non-Celiac Gluten Sensitivity Celiac Disease Allergic Rx Gluten hypersensitivity Gluten Intolerance Mild gluten sensitivity Adapted from Verdu EF, et al. Am J Gastroenterol 2009;104:1587-94; & Nijeboer P. J Gastrointestin Liver Dis, December 2013 Vol. 22 No 4: 435-440 • IBS patients received either gluten or placebo in the form of two bread slices plus one muffin per day with a gluten-free diet for up to 6 weeks. • Symptoms were evaluated using a visual analog scale and markers of intestinal inflammation, injury, and immune activation were monitored. • Non-celiac gluten sensitivity: 30% Biesiekierski JR et al. Am J Gastro 2011 106 (3)508-514. Gluten Induces Symptoms in IBS • uncontrolled symptoms – 13/19 (68%) gluten – 6/15 (40%) placebo (P=0.0001) • patients were significantly worse with gluten within 1 week overall symptoms (P=0.047) pain (P=0.016) bloating (P=0.031) satisfaction with stool consistency (P=0.024) – tiredness (P=0.001) – – – – Biesiekierski JR et al. Am J Gastro 2011 106 (3)508-514. Non-Celiac Wheat Sensitivity in IBS: A Distinct Clinical Condition • IBS pts N=920 • IBS patients N=276 “gluten sensitivity” but non-celiac • 2 weeks on wheatcontaining diet and • 2 weeks on placebo • Changes in symptom severity over baseline during DBPC wheat challenge Carroccio A. et al. Am J Gastroenterol 2012; 107:1898–1906 Diets For Microbiome Restoration Specific carbohydrate diet – Undigested carbohydrates feed “downstream” bacteria further dysbiosis FODMAP Diet: -- Low prebiotic, lactose, fructans, galactans, polyols (fermentable oligo- and disaccharides, monosaccharides, polyols) Soluble fiber (e.g., modified citrus pectin, vegetable fibers) – Paleolithic man consumed > 100 g fiber/day – Increases beneficial short-chain fatty acids (SCFAs) Fermented foods (e.g., Body Ecology Diet) – Restore and maintain “inner ecology” through: – Cultured foods – Decreasing sugars and carbohydrates Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols • Family of poorly absorbed, short-chain carbohydrates – Lactose – Fructose – Polyols – Fructans – Galactans (galacto-oliogsaccharides ) • Highly fermentable in the presence of gut bacteria De Roest, Int J Clin Prac, 2013; Gibson, J Gastroenterol Hepatol, 2010; Gibson – Am J Gastroenterol, 2012: Ong, et al, J Gastroenterol Hepatol, 2010; Staudacher J Hum Nutr Diet, 2011 FODMAP Fructose Polyols Lactose Fructans and Galactans High FODMAP food sources Apples, pears, watermelon, honey, fruit juices, dried fruits, highfructose corn syrup Sugar alcohols (sorbitol, maltitol, mannitol, xylitol, and isomalt), stone fruits, avocado, mushrooms, cauliflower Milk (cow, goat, sheep), yogurt, soft cheeses (ricotta, cottage) Wheat, rye, garlic, onions, artichokes, asparagus, inulin, soy, leeks, legumes, lentils, cabbage, Brussels sprouts, broccoli Alternative lower FODMAP food sources Citrus, berries, bananas, grapes, honeydew, cantaloupe, kiwifruit Sweeteners, such as sugar, glucose, other artificial sweeteners not ending in “-ol” (Stevia) Lactosefree dairy products, rice milk, hard cheeses Starches, such as rice, corn, potato, quinoa. Vegetables, such as winter squash, lettuce, spinach, cucumbers, bell peppers, green beans, tomato, eggplant FODMAPs Elimination Approach 1. Eliminate all high FODMAPs foods from the diet for a trial period of 2 - 6 weeks. FODMAPs food classes: Lactose Polyols Fructose Fructans Galactooligosaccharides 2. Challenge - Add foods from one FODMAP class using a small and then larger load and observe for symptoms – continue through all categories Catsos P. IBS—Free at Last! Portland, ME: Pond Cove Press; 2009, 2012; Shepherd SJ, Gibson PR. Fructose malabsorption and symptoms of irritable bowel syndrome: guidelines for effective dietary management. J Am Diet Assoc. 2006;106:1631–1639. 62 Low FODMAP vs. Standard Diet for IBS Staudacher HM, et al. J Hum Nutr Diet 2011 Baseline fecal bifidobacteria concentration in IBS patients compared with change in bifidobacteria concentration after 4 wk of fermentable CHO restriction Staudacher HM et al. J. Nutr. 142: 1510–1518, 2012. Proportion of patients showing improvement (%) * p<0.05 * * * * Improvement of mean daily symptom score after 4 wk of habitual diet (control) or fermentable CHO restriction (intervention) Staudacher HM et al. J. Nutr. 142: 1510–1518, 2012. Halmos et al Gastro Jan 2014;146:67-75. Mean overall gastrointestinal symptoms from the (A) IBS cohort and the (B) healthy cohort using a VAS during baseline, low FODMAP and typical Australian diets. Symptoms improved significantly on low FODMAP compared with baseline and the typical Australian diet for the IBS cohort. No differences were observed between any of the diets in the healthy cohort Mean symptoms of (A) bloating, (B) abdominal pain, and (C) passage of wind from the IBS cohort using a VAS while following a typical Australian and low FODMAP diet. Mean dissatisfaction with stool consistency in (D) IBS-D and (E) IBS-C after 8–21 days of typical Australian and low FODMAP diets are indicated with a bold line. Symptoms were significantly lower on low FODMAP compared with a typical Australian diet in all measured symptoms Bloating, Abdominal Pain, Dissatisfaction With Stool Consistency, and Composite Scores of All Three Symptoms in IBS and Healthy Participants While Following Low FODMAP and Typical Australian Diets Halmos et al Gastro Jan 2014;146:67-75. Food Reactions and IBS Summary • Patients with IBS-D/M should be screened for celiac disease • Expected US prevalence in IBS pts is ≤1% but likely varies based upon population genetics • Lactose intolerance may be more common in IBS • Clinical implications of CHO intolerance may be different in persons with than without IBS • Food can affect GI function and sensation • Mounting evidence suggests that dietary & lifestyle interventions can improve symptoms in a subset of IBS sufferers British Dietetic Association IBS Management Guidelines Review study, 30 papers met inclusion criteria. 1. Remove milk and dairy products: lactose intolerance 2. Avoid wheat bran. Ground flax may be tried for 3 month trial for IBS-C. 3. Try low FODMAP diet and institute challenge of foods to individualize plan 4. Probiotics: consider after FODMAP diet. Results vary, so try one product at a time for 4 weeks. 5. Empirical and elimination diets: – Initial phase 2-4 weeks – Reevaluate McKenzie Y.A. (2012) J Hum Nutr Diet. 25, 260-274 Figure 3. Proposed Algorithm for the Management of Suspected Food Intolerances in the Irritable Bowel Syndrome (IBS). Mullin et al JPEN 2014 In Press Nutritional Tools for Your IBS Patient • Anti-anxiety Herbs • Anti-microbials for SIBO • Artichoke leaf extract • Elimination Diet • Soluble Fiber • FODMAP restricted diet/Carbohydrate restricted diet • Melatonin • Peppermint Oil • Probiotics • Tumeric Summary Evidence for the Complementary of Nutrition Therapies in the Irritable Bowel Syndrome (IBS). Mullin et al JPEN 2014 In Press